Identifying cancer biomarkers by mass spectrometry‐based glycomics
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Correlations between aberrant glycosylation and cancer have been established for decades. The major advances in mass spectrometry (MS) and separation science have rapidly advanced detailed characterization of the changes associated with cancer development and progression. Over the past 10 years, many reports have described MS‐based glycomic methods directed toward comparing the glycomic profiles of different human specimens collected from disease‐free individuals and patients with cancers. Glycomic profiling of glycoproteins isolated from human specimens originating from disease‐free individuals and patients with cancers have also been performed. Profiling of native, labeled, and permethylated glycans has been acquired using MALDI‐MS and LC‐MS. This review focuses on describing, discussing, and evaluating the different glycomic methods employed to characterize and quantify glycomic changes associated with cancers of different organs, including breast, colon, esophagus, liver, ovarian, pancreas, and prostate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Intracellular Functions of N-Linked Glycans
Helenius, A., & Aebi, A. M. (2001) · Science · doi:10.1126/science.291.5512.2364 · Cited by 2,405
Analysis of glycans derived from glycoconjugates by capillary electrophoresis‐mass spectrometry
Mechref, Y. (2011) · ELECTROPHORESIS · doi:10.1002/elps.201100342 · Cited by 64
Self-citation
Cited by
Paleček, E., Tkáč, J., Bartošík, M., Bertók, T., Ostatná, V., & Paleček, J. (2015) · Chemical Reviews · doi:10.1021/cr500279h · Cited by 319
Solís, D., Bovin, N. V., Davis, A. P., Jiménez-Barbero, J., Romero, A., Roy, R., Smetana, K., & Gabius, H.-J. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.03.016 · Cited by 222
Leung, K. K., Wilson, G. M., Kirkemo, L. L., Riley, N. M., Coon, J. J., & Wells, J. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917947117 · Cited by 83
Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?
Azevedo, R., Peixoto, A., Gaiteiro, C., Fernandes, E., Neves, M., Lima, L., Santos, L. L., & Ferreira, J. A. (2017) · Oncotarget · doi:10.18632/oncotarget.19433 · Cited by 39
“Still, a plethora of mass spectrometrybased analytical approaches have been developed to address these challenges [8, 9] and the standardization of high-throughput glycomics is expected to boost our knowledge on bladder cancer glycobiology in the near future.”
BackgroundIntroduction to glycopathology: The concept, the tools and the perspectives
Gabius, H.-J., & Kayser, K. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-4 · Cited by 31
“Their availability opens the door to comparative studies of glycan sequences in clinical specimens in the quest to define glycobiomarkers for diseases such as cancer, CA19-9 being an example [13-15].”
Background
Metadata
- Authors
- Mechref, Y., Hu, Y., Garcia, A., & Hussein, A.
- Venue
- ELECTROPHORESIS
- Publisher
- Wiley
- Published
- 2012-06-28
- Volume
- 33
- Issue
- 12
- Pages
- 1755-1767
- ISSN
- 0173-0835 (ISSN-L)
- 1522-2683
- OpenAlex
- W1554431740
- Cited by
- 141
- References
- 4
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.